Bryan W. Day

Gardens Point
QLD, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

From data silos to integrated diagnosis: multimodal machine learning in glioblastoma.

From data silos to integrated diagnosis: multimodal machine learning in glioblastoma.

Journal: Frontiers in oncology

Published: June 18, 2026

Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease.

Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease.

Journal: Science advances

Published: January 30, 2026

A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 04, 2025

First cell-patterning of primary, patient-derived mesenchymal glioblastoma brain cancer cells on parylene-C/SiO2 substrates.

First cell-patterning of primary, patient-derived mesenchymal glioblastoma brain cancer cells on parylene-C/SiO2 substrates.

Journal: PloS one

Published: September 21, 2025

Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Journal: Oncogene

Published: March 03, 2025

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.

Journal: Cell reports. Medicine

Published: December 28, 2024

Spatial analysis of a complete DIPG-infiltrated brainstem reveals novel ligand-receptor mediators of tumour-to-TME crosstalk.

Spatial analysis of a complete DIPG-infiltrated brainstem reveals novel ligand-receptor mediators of tumour-to-TME crosstalk.

Journal: Acta neuropathologica communications

Published: October 31, 2024

Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma.

Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma.

Journal: Nature communications

Published: October 17, 2024

Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives.

Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives.

Journal: Acta neuropathologica communications

Published: September 17, 2024

Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastoma.

Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastoma.

Journal: Cancer letters

Published: July 24, 2024

EphA3 CAR T cells are effective against glioblastoma in preclinical models.

EphA3 CAR T cells are effective against glioblastoma in preclinical models.

Journal: Journal for immunotherapy of cancer

Published: July 18, 2024

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Journal: Oncogene

Published: February 14, 2024

Showing 1-12 of 96

Last Updated: 09/26/2026